Atlas Trials

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Clinical trial NCT05503953 · COMPLETED

Trial details

NCT number
NCT05503953
Sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Essential Hypertension
Start date
2022-10-18
Primary completion
2025-06-10
Enrollment
318

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.